Despite improvements in safety of plasma transfusion due to correct selection of the donors, performance of serological screening (HIV1-2, HTLV1-2, HCV, HBV, CMV, VDRL and TPHA) and nucleic acid testing (NAT) for HIV & HCV, some infectious transmissions, particularly virus transmissions still remain.These risks are due to the known major serologically screened viruses at the window period, unscreened viruses, undetectable viruses and also new, emerging, re-emerging, or mutated infectious agents resulting from the climatic, ecologic and sociologic changes and travels.In France, the estimation of risks for conventional virus transmission by blood labile products was performed by the health authority “afssaps” (J.Pillonel et all, 2009).

The emerging Pathogen “ Candida auris” is attracting considerable international attention due to its rising reports, transmission through health professionals, high rate of treatment failure and resistance to multiple antifungal agents, particularly fluconazole. In spite of the global emergence of C. auris, epidemiological data and true prevalence of infections due to this organism are not clearly determined due to incapability of conventional and biochemical identification methods. Consequently, this species is erroneously identified as C. haemulonii or Rhodotorula glutinis because of their close phenotypical and biochemical resemblance. Therefore, awareness of serious menace posed by C. auris is of great importance for physicians and health laboratory personnel. This awareness could play a beneficial role in prevention of healthcare-associated outbreaks, timely and definite diagnosis, prompt initiation of C. auristargeted therapy, and subsequently improving treatment outcomes. This review aimed to discuss the epidemiology, drug resistance, diagnostic challenges, the mode of transmission, and the strategies for prevention of C. auris-related infections.